drugset / Trial / NCT01142700
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I
RandomizedParallel-groupDouble-blindTreatment
Summary
Based on 12-week on-treatment data, at least 1 dose of BMS-824393 can be identified which is safe, well tolerated, and has sufficient antiviral activity to progress to late stage clinical trials when combined with pegIFNα/RBV for treatment of chronically infected hepatitis C virus genotype 1 treatment-naive subjects.
Timeline
- Start
- 2010-07
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-824393 | Unknown | 10 mg | Oral |
| Subject | BMS-824393 | Unknown | 30 mg | Oral |
| Subject | BMS-824393 | Unknown | 100 mg | Oral |
| Background | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Background | Ribavirin | Small molecule | 400 mg | Oral |
| Background | Ribavirin | Small molecule | 600 mg | Oral |